Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7668MR)

This product GTTS-WQ7668MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in B-cell malignancies research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7668MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ353MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ14563MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ15713MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VIR-7831
GTTS-WQ14625MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ7105MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ12681MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ9119MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ15586MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW